Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEECur trial in relapsed or refractory Ewing sarcoma
ACTRN12618001825246Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of ifosfamide, lenvatinib, carboplatin, etoposide, gemcitabine and 5 more in Ewing sarcoma and Ewing-like sarcoma (6 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Nov 2018; status: recruiting.
02
Drugs
ifosfamidelenvatinibcarboplatinetoposidegemcitabine
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on ACTRN12618001825246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001825246.